Seagen (United States)

Publications

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

Craig L. Bennett , Jacinda R. Christie , Fred Ramsdell +7 more

IPEX is a fatal disorder characterized by immune dysregulation, polyendocrinopathy, enteropathy and X-linked inheritance (MIM 304930). We present genetic evidence that different...

2001 Nature Genetics 3293 citations

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy , Sherene Loi , Alicia Okines +29 more

In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in b...

2019 New England Journal of Medicine 1224 citations

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Thomas Powles , Jonathan E. Rosenberg , Guru Sonpavde +10 more

Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who had previousl...

2021 New England Journal of Medicine 1021 citations

Institution Info

Type: company
Country: US
Publications: 3
Citations: 5,538

External Links

Identifiers

ROR: https://ror.org/01vwesc15

Publications

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Affiliated Researchers

Maria Corinna Palanca-Wessels

Luke Walker

Wentao Feng

Phillip F. Chance

Institution Info

External Links

Identifiers

Research Output Over Time